Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice

Jie Gao, Shumei Ren, Gabrielle Choonoo, Guoying Chen, Davor Frleta, Jun Zhong, Namita T. Gupta, Prachi Sharma, A. Oyejide, Gurinder S. Atwal, Lynn E. Macdonald, Andrew Murphy, Frank KuhnertDisease 2023 · DOI

TL;DR

Researchers have developed a novel humanized mouse model that better recapitulates Sezary Syndrome (SS), a rare and aggressive form of T-cell lymphoma. By engineering mice to express human Interleukin-15 (IL-15), they significantly improved the engraftment and growth of SS patient cells, paving the way for more effective preclinical drug testing and a deeper understanding of the disease.

What Problem Does This Paper Address?

Sezary Syndrome (SS) is a challenging hematologic malignancy with limited treatment options and a significant lack of effective small-animal models for research. Existing models often fail to capture the full spectrum of the human disease, particularly its ability to spread to the periphery and lymphoid tissues. A key hurdle in developing these models is the species-specific nature of cytokines and growth factors, meaning mouse versions often don't effectively stimulate human cells. This study tackles the critical need for better preclinical models by focusing on Interleukin-15 (IL-15), a cytokine known to be important for T-cell function, and investigating its role in SS.

Methods

The researchers employed a multi-pronged approach:

  • In vitro proliferation assays: They tested the effect of various cytokines (IL-2, IL-7, IL-15, IL-4, IL-13, IL-6, IL-9) on the proliferation of the Hut78 CTCL cell line to identify key growth factors.
  • Genetic Humanization of Mice: They utilized a genetically engineered immunodeficient mouse strain (SRG mice) and modified it to express human IL-15 instead of mouse IL-15. This "humanized" mouse model (SRG15) was designed to overcome the species barrier for IL-15 signaling.
  • Patient-Derived Xenograft (PDX) Models: They intravenously injected peripheral blood samples from SS patients into sublethally irradiated mice (NSG, SRG, and SRG15). This allowed them to assess the engraftment and growth of human SS cells in different mouse models.
  • Serial Passaging: To evaluate the stability and reproducibility of the PDX models, they serially passaged cells from established tumors into new recipient mice.
  • Immunophenotyping and Histology: They used flow cytometry to analyze the surface markers of the engrafted cells and performed H&E staining and immunohistochemistry on tissue samples to assess pathological features like skin infiltration and the presence of cerebriform nuclei characteristic of Sezary cells.
  • Single-Cell RNA Sequencing (scRNA-seq) and TCR Sequencing: To understand the molecular underpinnings of engraftment and potential tissue-specific adaptations, they performed scRNA-seq on sorted CD4+ cells from patient samples and PDX models. TCR sequencing was used to track clonal expansion and selection.

Datasets

The study utilized:

  • SS Patient Samples: Peripheral blood samples from four SS patients were used for xenotransplantation.
  • Control Samples: Peripheral blood mononuclear cells (PBMCs) from an unaffected donor were used for scRNA-seq analysis as a control.
  • Hut78 Cell Line: A cytokine-independent CTCL cell line used for in vitro proliferation assays.

No new benchmarks were introduced; rather, the study aimed to improve existing PDX modeling capabilities.

Key Insights and Ideas

  • IL-15 is a critical growth factor for SS cells: The study strongly implicates IL-15 as a key driver of SS cell proliferation, both in vitro and in vivo.
  • Humanized IL-15 mice are superior for SS PDX models: The SRG15 mice, engineered to express human IL-15, significantly outperformed conventional immunodeficient mice (NSG, SRG) in terms of SS patient sample engraftment rates and disease burden.
  • SRG15 models recapitulate key human disease features: The generated PDX models successfully mimicked critical aspects of SS, including skin infiltration, spread to lymphoid organs, and the characteristic immunophenotype of Sezary cells.
  • Skin-resident Sezary cells exhibit a distinct malignant gene signature: scRNA-seq revealed that Sezary cells residing in the skin of the humanized mice displayed a more pronounced malignant gene expression profile compared to those in the spleen, suggesting tissue-specific regulation.
  • Strong clonal selection occurs in vivo: TCR sequencing indicated that a specific subclone of Sezary cells, not necessarily the dominant one in the original patient sample, was strongly selected for and expanded in the SRG15 mouse model.

Key Results

  • IL-15 showed the most potent proliferation-inducing activity on Hut78 cells in vitro compared to other tested cytokines.
  • Three out of four SS patient samples engrafted successfully in SRG15 mice, while only one engrafted in SRG mice and none in NSG mice.
  • Leukemic disease burden was significantly higher and developed faster in SRG15 mice compared to SRG mice.
  • Engrafted Sezary cells in SRG15 mice exhibited the characteristic CD4+ immunophenotype with loss of CD7 expression.
  • Histological analysis of SRG15 mice revealed lymphocyte infiltration into the skin with cerebriform nuclei, mimicking human SS pathology.
  • Leukemic cells also infiltrated the liver and spleen, leading to splenomegaly in SRG15 mice.
  • The established SS PDX models could be serially passaged in SRG15 mice, maintaining their dependence on human IL-15.
  • scRNA-seq analysis showed that ~95% of skin-resident CD4+ cells in engrafted mice displayed a malignant gene signature, while splenic cells were quantitatively normal.

Limitations and Future Work

  • Limited number of patient samples: The study used only four SS patient samples, which is a limitation given the rarity of the disease. The authors acknowledge this and suggest that adoption of the IL-15 humanization platform by other researchers will help further validate these findings.
  • Potential for cytokine redundancy: While IL-15 is critical, the in vitro results showed that IL-2 and IL-4 also induced proliferation in Hut78 cells. This suggests potential cytokine redundancy and might imply that IL-15 blockade alone could be circumvented by other signaling pathways.
  • Tissue-specific gene expression: The observed differential gene expression between skin- and spleen-resident Sezary cells raises questions about the host factors driving these differences, which warrants further investigation.
  • Future Directions: The authors propose exploring the humanization of other non-cross-reactive cytokines (like IL-2 and IL-4) in SRG mice to potentially further enhance engraftment and disease burden. They also highlight the utility of the SRG15 model for preclinical testing of therapeutic agents targeting Sezary cells and suggest its broader application for other T and NK cell-derived hematologic malignancies. The importance of thorough molecular characterization of PDX models to maximize their translational impact is also emphasized.

Summary updated

Abstract

Sezary syndrome (SS) is a rare, aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) that lacks adequate therapeutic options and representative small-animal models. Here, we demonstrate that IL-15 is a critical CTCL growth factor. Importantly, an immunodeficient knock-in mouse model genetically engineered to express human IL-15 uniquely supported the growth of SS patient samples relative to conventional immunodeficient mouse strains. SS patient-derived xenograft (PDX) models recapacitated key pathological features of the human disease, including skin infiltration and spread of leukemic cells to the periphery, and maintained the dependence on human IL-15 upon serial in vivo passaging. Detailed molecular characterization of the engrafted cells by single-cell transcriptomic analysis revealed congruent neoplastic gene expression signatures but distinct clonal engraftment patterns. Overall, we document an important dependence of Sezary cell survival and proliferation on IL-15 signaling and the utility of immunodeficient humanized IL-15 mice as hosts for SS - and potentially other T and NK cell-derived hematologic malignancies - PDX model generation. Furthermore, these studies advocate the thorough molecular understanding of the resultant PDX models to maximize their translational impact.
BibTeX
@inproceedings{gao2023microenvironment,
  author = {Jie Gao and Shumei Ren and Gabrielle Choonoo and Guoying Chen and Davor Frleta and Jun Zhong and Namita T. Gupta and Prachi Sharma and A. Oyejide and Gurinder S. Atwal and Lynn E. Macdonald and Andrew Murphy and Frank Kuhnert},
  title = {{Microenvironment-dependent growth of Sezary cells in humanized IL-15 mice}},
  booktitle = {Disease},
  year = {2023},
  doi = {10.1242/dmm.050190},
}
Figure